Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22640901 | 1.00 | ACE (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL22640912 | 1.00 | ACE (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL24616731 | 1.00 | ACE (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL24616717 | 1.00 | ACE (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL22640932 | 0.98 | PTPN1 (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL24616810 | 0.98 | PTPN1 (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL22640906 | 0.98 | PTPN1 (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL22640907 | 0.98 | PTPN1 (0.47) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL24616730 | 0.97 | ACE (0.45) | ACEGNPATPTPN1TASP1SIRT5 | |
| SCHEMBL24616714 | 0.97 | ACE (0.45) | ACEGNPATPTPN1TASP1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | claimed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | claimed |
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | disclosed |
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | disclosed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020225245-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | IPROTEOS, S.L. (ES) | 2020-11-12 | — | — | WO | disclosed |
| EP-3736284-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Iproteos S.L (ES) | 2020-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | LDLR, APOB, HDLBP | ACE 1604/4885GNPAT 1017/4885PTPN1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.